Want to see IOVA full AI Analyst Report?
Top Page
Iovance Biotherapeutics
(NASDAQ:IOVA)
Select Model
Select Model
Rating:58Neutral
Price Target:
$4.50
▲(16.58% Upside)
Action:Reiterated
Date:07/03/26
The score is held back primarily by weak financial performance—large ongoing losses and heavy cash burn—despite improving revenue. Offsetting this, the latest earnings call points to strong commercial momentum and clearer revenue guidance with an extended cash runway, while the stock’s technical setup is moderately constructive. Valuation remains challenged due to negative earnings, and corporate events are a small net positive with some dilution risk.
Positive Factors
Commercial revenue acceleration
Sustained, high-single quarter revenue growth reflects that AMTAGVI has transitioned from trial-stage to a meaningful commercial product. Over months this supports predictable per-patient revenue, broadens payer negotiations, and validates the sales model needed to scale treatment volumes and long-term revenue cadence.
Negative Factors
Large operating cash burn
Persistent, sizable negative operating and free cash flow creates an ongoing need for financing and constrains reinvestment. Unless revenues scale faster than costs, cash burn will force continued capital raises or spending cuts, which can dilute shareholders or slow commercialization and R&D progress over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial revenue acceleration
Sustained, high-single quarter revenue growth reflects that AMTAGVI has transitioned from trial-stage to a meaningful commercial product. Over months this supports predictable per-patient revenue, broadens payer negotiations, and validates the sales model needed to scale treatment volumes and long-term revenue cadence.
Read all positive factors
Iovance Biotherapeutics (IOVA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.95B
Dividend YieldN/A
Average Volume (3M)13.51M
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue Growth34.26%
EPS Growth23.00%
CountryUS
Employees838
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.92
Shares Outstanding446,502,400
10 Day Avg. Volume13,499,322
30 Day Avg. Volume13,508,678
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.40
Price to Sales (P/S)3.70
P/FCF Ratio-2.90
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue4.40
Enterprise Value/Gross Profit3.84
Enterprise Value/Ebitda-3.91
Forecast
1Y Price Target
$9.80Price Target Upside153.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$362.04M
Iovance Biotherapeutics Business Overview & Revenue Model
Company Description
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune syste...
How the Company Makes Money
Iovance makes money primarily by selling its FDA-approved autologous cell therapy, AMTAGVI (lifileucel), in the United States. Revenue is generated when treatment centers order and administer AMTAGVI for eligible patients; because it is an individ...
Iovance Biotherapeutics Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call conveyed strong commercial momentum and meaningful operational progress: high single-quarter revenue growth (~45% YoY), robust Amtagvi demand (+38% YoY), tighter Q2/full-year guidance, expanded manufacturing control, R&D cost reductions, extended cash runway into 2028, and encouraging early clinical signals (e.g., 40% ORR in serous endometrial cancer). Near-term headwinds include a one-time facility-related margin hit (Q1 gross margin ~41%), some quarter-to-quarter revenue volatility in Proleukin, continued use of ATM financing, and the usual clinical/regulatory and enrollment execution risks. Overall, the positives—notably accelerating commercial traction, pipeline advances, and improved cost discipline—substantially outweigh the listed challenges.Positive Updates
Strong Top-Line Growth
First quarter revenue of $71 million, an approximately 45% year-over-year increase, driven by strong Amtagvi demand.
Negative Updates
Temporary Manufacturing Disruption Impacted Q1 Margins
A temporary capacity reduction to complete facility upgrades contributed to one-time nonrecurring costs and constrained Q1 gross margin to ~41%, below the ~50% level referenced for Q4 2025.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Top-Line Growth
First quarter revenue of $71 million, an approximately 45% year-over-year increase, driven by strong Amtagvi demand.
Read all positive updates
Company Guidance
Iovance provided tight near‑term and full‑year financial guidance and several supporting metrics: Q1 revenue was $71M (≈45% YoY), driven by Amtagvi $60M (↑38% YoY) and Proleukin $11M; gross‑to‑net remained <2% and Q1 gross margin was ~41% (affected by one‑time facility upgrade costs); R&D expense declined for a third consecutive quarter (‑18% vs prior period, ‑12% vs prior quarter); cash & equivalents were ~$319M at March 31 with management expecting to fund operations into 2028. For Q2 they forecast total revenue of $86–88M (Amtagvi $79–81M, roughly a 23% increase versus their prior highest quarterly Amtagvi revenue in Q4 2025), and full‑year 2026 revenue of $350–370M (Amtagvi + Proleukin), with margins expected to trend higher in 2026 excluding one‑time items; management also reiterated a >$1B U.S. peak sales trajectory for Amtagvi + Proleukin, noted March was the largest Amtagvi month to date, physician awareness rose to 70% (from 50% six months earlier), and the company is targeting roughly 110 ATCs by year‑end.Iovance Biotherapeutics Financial Statement Overview
Summary
Income Statement
33
Negative
Balance Sheet
70
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 285.61M | 263.50M | 164.07M | 1.19M | 0.00 | 0.00 |
| Gross Profit | 327.04M | 256.22M | 40.08M | -9.57M | 0.00 | 0.00 |
| EBITDA | -321.35M | -357.11M | -331.40M | -414.39M | -371.77M | -328.27M |
| Net Income | -353.86M | -390.98M | -372.18M | -444.04M | -395.89M | -342.25M |
Balance Sheet | ||||||
| Total Assets | 925.66M | 913.17M | 910.43M | 780.35M | 663.98M | 777.33M |
| Cash, Cash Equivalents and Short-Term Investments | 313.44M | 296.98M | 323.78M | 279.87M | 471.85M | 504.41M |
| Total Debt | 47.78M | 48.44M | 58.26M | 75.86M | 85.45M | 71.53M |
| Total Liabilities | 203.91M | 214.59M | 200.02M | 195.74M | 164.34M | 155.67M |
| Stockholders Equity | 721.75M | 698.58M | 710.40M | 584.61M | 499.64M | 621.66M |
Cash Flow | ||||||
| Free Cash Flow | -305.02M | -336.24M | -364.05M | -384.11M | -313.18M | -265.51M |
| Operating Cash Flow | -270.79M | -302.41M | -352.98M | -361.82M | -292.76M | -227.94M |
| Investing Cash Flow | 43.02M | 47.50M | -96.41M | -155.24M | 256.45M | 132.00K |
| Financing Cash Flow | 251.79M | 300.77M | 390.66M | 462.96M | 190.15M | 239.27M |
Iovance Biotherapeutics Technical Analysis
Positive
3.86
Price Trends
3.94
Positive
3.84
Positive
3.11
Positive
Market Momentum
0.09
Negative
52.88
Neutral
64.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IOVA, the sentiment is Positive. The current price of 3.86 is below the 20-day moving average (MA) of 4.15, below the 50-day MA of 3.94, and above the 200-day MA of 3.11, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 52.88 is Neutral, neither overbought nor oversold. The STOCH value of 64.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IOVA.
Iovance Biotherapeutics Risk Analysis
Iovance Biotherapeutics disclosed 83 risk factors in its most recent earnings report. Iovance Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Iovance Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.95B | -4.66 | -50.17% | ― | 34.26% | 23.00% | |
58 Neutral | $1.74B | -3.16 | -53.31% | ― | 213.96% | 25.74% | |
58 Neutral | $2.04B | -12.07 | -55.68% | ― | ― | 51.42% | |
56 Neutral | $2.13B | -13.89 | -44.10% | ― | 1205.52% | 81.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $1.34B | -4.97 | -45.27% | ― | -72.09% | -754.83% |
* Healthcare Sector Average
IOVA
Iovance Biotherapeutics
4.23
2.22
110.45%
VIR
Vir Biotechnology
9.96
4.46
81.09%
IMTX
Immatics
9.68
3.57
58.43%
NUVB
Nuvation Bio
5.81
3.67
171.50%
AMLX
Amylyx Pharmaceuticals Inc
17.77
9.36
111.30%
Iovance Biotherapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
Iovance updates outlook, highlighting Amtagvi growth and pipeline
Positive
Jul 2, 2026
On June 30, 2026, Iovance Biotherapeutics updated its corporate presentation, highlighting its position as a global leader in innovating and delivering TIL therapy and the commercial progress of Amtagvi in advanced melanoma. The company reported m...
Business Operations and StrategyExecutive/Board ChangesProduct-Related AnnouncementsShareholder Meetings
Iovance Shareholders Approve Expanded Capital Flexibility and Governance
Positive
Jun 10, 2026
On June 10, 2026, Iovance Biotherapeutics, Inc. held its annual stockholders’ meeting via webcast, with about 74% of outstanding shares represented. Shareholders elected six directors, approved executive compensation and annual say-on-pay fr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.